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Letter reSeArCH DNA substrate involving a self-complementary 25-mer zebularine (Z)-containing DNA, with two (CpG)-(ZpG) sites across 14 base pairs (Fig. 1b) . The structure of the DNMT3A-DNMT3L in complex with 25-mer DNA was determined at 2.65 Å resolution (Extended Data Fig. 1c ), revealing only one DNA duplex bending towards the DNMT3A-DNMT3L tetramer, with the two CpG sites simultaneously anchored by two DNMT3A monomers (Fig. 1c, d and Extended Data Fig. 2b ). Our data thus support the notion that the two DNMT3A monomers can co-methylate two adjacent CpG dinucleotides in one DNA-binding event 12, 13 . Despite being crystallized under different conditions, both DNMT3A-DNMT3L-DNA complexes are well aligned with their DNA-free state, with a root-mean-square deviation of 0.87 Å and 1.12 Å over 790 and 826 Cα atoms, respectively (Extended Data Fig. 2a ). Notably, in DNMT3A-DNMT3L-DNA complexes, zebularines are flipped out of the DNA helix and inserted deep into DNMT3A catalytic pockets, where they are covalently anchored by the catalytic cysteine C710 and hydrogen bonded to E756, R790, and R792 ( Fig. 1c and Extended Data Fig. 1d ). Because both structures reveal productive reaction states with consistent protein-DNA interactions, we focus on the structure of DNMT3A-DNMT3L in complex with 25-mer DNA for further analysis.
DNMT3A binding to DNA is mainly mediated by a loop from the target recognition domain (TRD) (residues R831-F848), the catalytic loop (residues G707-K721), and the homodimeric interface of DNMT3A, which together create a continuous DNA-binding surface (Figs 1d and 2a ). Accordingly, these segments exhibit the most prominent structural changes upon DNA binding: the TRD loop lacked electron density in the DNA-free structure of DNMT3A-DNMT3L 11, 12 , but became well defined upon DNA binding and penetrated into the DNA major groove for intermolecular contacts (Fig. 2a-c) ; additionally, the TRD loop is stabilized through hydrogen-bonding interactions with R882, the DNMT3A mutational hotspot among leukaemias 9, 10 , and Q886 from an adjacent helix (Fig. 2c) . Meanwhile, the catalytic loop residue V716 moves towards the DNA minor groove by approximately 2 Å, intercalating into the DNA cavity vacated because of zebularine base flipping (Fig. 2d, e ). Although no protein-DNA contact was observed for DNMT3L, two DNMT3L-contacting helices of DNMT3A are preceded by DNA-binding loops (Extended Data Fig. 2c ), reinforcing the notion that DNMT3L enhances DNMT3A functionality through stabilizing its DNA-binding sites 12 .
Recognition of CpG dinucleotides by DNMT3A is mediated by both catalytic and TRD loops. In particular, guanine of the target strand, G6 (G19′ ), is specified by a hydrogen bond between its O6 atom and the Nε atom of R836 from the TRD loop, as well as water-mediated hydrogen bonds between its N7 atom and the Nε and Oγ atoms of R836 and T834, respectively (Fig. 3a) . Meanwhile, the catalytic loop approaches the minor groove, where the backbone carbonyl oxygen of V716 forms a hydrogen bond with the N2 atom of the unpaired guanine G5′ (G20) (Fig. 3b ). Penetration of the catalytic loop also allows V716 and P718 to engage van de Waals contacts with the base of G6 (G19′ ), providing additional base-specific recognition (Fig. 3b ). No protein interaction was associated with C6′ (C19) of the non-target strand, providing an explanation for the observation that DNMT3A does not discriminate hemimethylated against unmethylated DNA 2 . Formation of the DNMT3A-DNA complex is also supported by various protein-DNA interactions flanking CpG, which involve electrostatic and/or hydrogen-bonding interactions of the TRD residues (R831, T832, T835, N838, and K841), catalytic loop residues (N711, S714, and I715) and DNMT3A-DNMT3A homodimeric interface residues (S881, R882, L883, and R887) with various DNA backbone or base sites ( Fig. 2a and Extended Data Fig. 3a-f ). These DNA-binding residues are highly conserved in DNMT3B (Extended Data Fig. 3g ), suggesting a similar substrate engagement mechanism used by the DNMT3 family.
To determine the roles for CpG-engaging residues R836 and V716 in the regulation of DNMT3A activity, we performed mutagenesis followed by enzymatic studies using CpG-, CpA-, or CpT-containing substrates ( Fig. 3c and Extended Data Fig. 4a, b ). First, wild-type DNMT3A (DNMT3A WT ) showed methylation efficiency for CpG-containing DNA more than 20-fold higher than for CpA-or CpT-containing DNA, confirming its well-known CpG specificity 14 . By contrast, mutation of R836 to alanine (R836A) enhanced methylation of CpA-and CpTcontaining DNA by 5.2-and 4.2-fold, respectively, but, as previously reported 15 , only led to slight change in CpG methylation. As a result, the relative CpG/CpA and CpG/CpT preference of the DNMT3A R836A enzyme was reduced by 4.5-and 3.7-fold, respectively, supporting a role for R836 in substrate specificity determination. Consistent with these observations, we solved the structure of the DNMT3A R836A -DNMT3L-DNA complex, which lacks R836-mediated hydrogen bonds to CpG without causing overall structural alterations (Extended Data Fig. 4c ). Mutation of V716 to glycine (V716G) abolished methylation T18′   T17′   C16′   T15′   3′  5′   V716′   N711′   T835′   R836′   R792′  S714′  T832′   E756′   R790′   V763′   R792′  P718′   I715′   A10′   G9′   A7′  A8′   C6′   G5′   C4′   A3′   T2′   G1′   T10   C9   T8   T7   G6   Z5   G4   T3   A2   C1   3′  5′   K841   V716   N711   T835   R836   R792   S714   T832   E756   R790   R882   N838   V763   R792   P718   I715   T14   T13   A11  A12   A14′   A13′   T12′   T11′   K841′  R882′   N838′   G0   T834′   L883′   L883   S881′   R887′   S881  R887   W   T834   R831 Letter reSeArCH of all tested substrates (Extended Data Fig. 4d ). These observations support the idea that R836-mediated CpG engagement contributes to substrate specificity whereas V716-mediated intercalation is essential for DNMT3A-mediated catalysis. The increased in vitro activity of DNMT3A R836A on CpA and CpT suggests that R836 might energetically influence the enzymology of DNMT3A, in addition to target recognition. In the case of CpG DNA, such an influence might be partly compensated by the R836-mediated hydrogen bonds, thereby ensuring the CpG specificity of DNMT3A.
Next, we introduced comparable levels of DNMT3A, either wild type or the above CpG-engagement-defective mutants, into ES cells with compound knockouts of DNMT1, DNMT3A, and DNMT3B (TKO) 16 , and detected a global increase in cytosine methylation after rescue with DNMT3A WT or DNMT3A R836A , but not DNMT3A V716G (Extended Data Fig. 4e, f ). Furthermore, genome-wide methylation profiling with enhanced reduced representation bisulfite sequencing (eRRBS), followed by calling of methylation using the previously described binomial model and false discovery rate (FDR)-based threshold 17, 18 , revealed that, in TKO ES cells reconstituted with DNMT3A WT , 58% and 42% of methylated cytosines were presented at CpG and non-CpG sites, respectively ( Fig. 3d and Extended Data Fig. 5a -c); by contrast, such a distribution was reversed in cells expressing DNMT3A R836A , with 31% and 69% of methylated cytosines found in CpG and non-CpG contexts ( Fig. 3d and Extended Data Fig. 5b , c). Consistently, relative to wild-type controls, the absolute methylation levels were found to be decreased at CpG, but increased at CpA and CpC, sites among cells with DNMT3A R836A , especially at sites showing intermediate-to-high levels of methylation ( Fig. 3e and Extended Data Figs 5d and 6a). These changes were persistent among all chromosomes, at both DNA strands and over all annotated genes (Extended Data Fig. 6b-d) , as exemplified by those detected at the major satellite DNA repeats ( Fig. 3f ) and gene-coding regions of Foxp1 and Dock1 (Extended Data Fig. 6e ). Sanger bisulfite sequencing further validated eRRBS results at major satellite repeats in ES cells 19 (Fig. 3g and Extended Data Fig. 7 ). DNMT3A V716G abolished both CpG and non-CpG methy lations at major satellite DNA (Extended Data Fig. 7b-d) . The above observation that DNMT3A R836A decreases overall CpG methylations in TKO cells might be due to competition of non-CpG as a potential substrate for this mutant enzyme. Collectively, we demonstrate that engaging CpG by the R836 side chain ensures DNMT3A substrate specificity in cells.
Notably, heterozygous mutation of DNMT3A at its DNA-binding residues, such as S714, V716, P718, R792, T835, R836, N838, K841, and R882 (Figs 2a and 4a, b), occurs recurrently in haematological cancer 9,10,20 and overgrowth syndrome 21 . Although recent studies support a dominant-negative effect of the hotspot R882H mutation on DNMT3A-mediated methylation, possibly through affecting DNMT3A tetramerization [22] [23] [24] [25] , our structural observation raises the possibility that interfering with the DNA binding via residue substitution also results in functional impairment of DNMT3A during pathogenesis. Indeed, in vitro enzymatic assays showed the significantly reduced activity for all tested DNA-binding mutants, with the most pronounced effect observed for V716D, R792H, and K841E ( Fig. 4c and Extended Data Fig. 8a-d ). Consistently, expression of these three mutants in TKO ES cells failed to restore global DNA methylation (Extended Data Fig. 8e , f). It is worth noting that, although DNMT3A R836W exhibited modestly reduced overall activities (Extended Data Fig. 8c , f), its activities for non-CpG methylations were found to be significantly increased at the major satellite DNA in TKO cells and in in vitro enzymatic assays (Extended Data Fig. 8g , h), suggesting a potential role for R836W in the redistribution of CpG versus non-CpG methylations in diseased cells. Given a largely heterozygous feature of DNMT3A mutations in leukaemia, we also queried whether the DNA-binding-defective mutants of DNMT3A inhibit functionality of DNMT3A WT . To test this, we turned to a co-expression system used previously for studying the dominant-negative DNMT3A R882H mutant 23 , and reconstituted wild-type and mutant DNMT3A in equal amounts into TKO ES cells ( Fig. 4d ). Relative to expression of wild type alone, co-expression of DNMT3A V716D , DNMT3A R792H , or DNMT3A K841E with DNMT3A WT significantly decreased overall cytosine methylation ( Fig. 4d ). Together, we show that the DNMT3A mutants defective in substrate binding not only decrease activity but also interfere with that of DNMT3A WT .
We further ectopically expressed the above DNMT3A mutants in TF-1 cells, a model used for studying leukaemia-associated gene mutation 26 . Through DNA methylation array profiling and bisulfite sequencing validation, we observed a significant reduction in overall CpG methylations in TF-1 cells stably expressing DNMT3A V716D , DNMT3A R792H or DNMT3A K841E , relative to control; by contrast, ectopic expression of DNMT3A WT induced hypermethylation ( Fig. 4e and Extended Data Fig. 9 ). There was significant overlap among CpG sites showing hypomethylation due to expression of DNMT3A V716D , DNMT3A R792H , or DNMT3A K841E (Extended Data Fig. 10a ), indicating their common effect on epigenomic deregulation. Reduced methylation Letter reSeArCH of these commonly affected sites was also detected after transduction of other leukaemia-associated substrate-binding mutations of DNMT3A (P718L, T835M, R836W, and N838D), although it did not induce hypomethylation globally (Extended Data Fig. 10b , c). Binding of wild-type or mutant DNMT3A was comparable at tested loci showing methylation changes (Extended Data Fig. 10d , e). Given that epigenetic deregulation promotes TF-1 cell transformation characterized by cytokineindependent growth 26 , we queried whether the DNA-binding-defective mutation of DNMT3A causes a similar transformation of this model. We found that, under cytokine-supporting conditions, TF-1 cells expressing wild-type or mutant DNMT3A exhibited comparable proliferation (Extended Data Fig. 10f ). By contrast, those expressing a DNA-binding-defective mutant, but not DNMT3A WT , had significant cytokine-independent growth capability ( Fig. 4f and Extended Data Fig. 10g ). Collectively, we demonstrate that the DNA-binding residues of DNMT3A are vital for establishing appropriate CpG methylation in haematological cells and that their somatic mutations detected in patients with leukaemia promote transformation. Supplementary Information is available in the online version of the paper.
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Protein expression and purification. The gene fragments encoding residues 628-912 of human DNMT3A (NCBI accession number NM_022552) and residues 178-386 of human DNMT3L were inserted in tandem into a modified pRSFDuet-1 vector (Novagen). The DNMT3A sequence was separated from the preceding His 6 -SUMO tag by a ubiquitin-like protease (ULP1) cleavage site. Expression and purification of the DNMT3A-DNMT3L complex followed a previously described protocol 27 . In brief, the His 6 -SUMO-DNMT3A fusion protein and DNMT3L were co-expressed in Escherichia coli BL21 DE3 (RIL) cell strains and purified using a Ni 2+ -NTA column. Subsequently, the His 6 -SUMO tag was removed through ULP1-mediated cleavage, followed by ion exchange chromatography on a Heparin column. For enzymatic assays, the DNMT3A-DNMT3L complex was further purified through size-exclusion chromatography on a HiLoad 16/600 Superdex 200 pg column (GE Healthcare), and concentrated to 0.1-0.3 mM in a buffer containing 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.1% β -mercaptoethanol, and 5% glycerol. To generate the covalent DNMT3A-DNMT3L-DNA complex, an 11-mer single-stranded DNA that was in-house synthesized to contain 2′ -deoxy zebularine 28 (5′ -CATGdZGCTCTC-3′ ; dZ, 2′ -deoxyzebularine) was annealed with a 10-mer single-stranded DNA (5′ -AGAGCGCATG-3′ ) before reaction with the DNMT3A-DNMT3L complex in the presence of 20 mM Tris-HCl (pH 7.5), 50 mM NaCl, 20% glycerol, and 40 mM DTT at room temperature. In addition, a 25-mer zebularine-containing DNA (5′ -GCATGZGTTCTAATTAGAACGCATG-3′ ; Z, zebularine) was self-annealed and used to form a second DNMT3A-DNMT3L-DNA complex or the DNMT3A R836A -DNMT3L-DNA complex. The reaction products were further purified through a HiTrap Q XL column (GE Healthcare), followed by size-exclusion chromatography on a HiLoad 16/600 Superdex 200 pg column. The final samples for crystallization of the productive DNMT3A-DNMT3L-DNA complexes contained about 0.1-0.2 mM covalent DNMT3A-DNMT3L-DNA complexes, 0.3 mM AdoHcy, 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.1% β -mercaptoethanol, and 5% glycerol. Crystallization conditions and structure determination. The crystals for the covalent complex of DNMT3A-DNMT3L with the 10/11-mer DNA were generated by the hanging-drop vapour-diffusion method at 23 °C, from drops mixed from 0.5 μ l of DNMT3A-DNMT3L-DNA solution and 0.5 μ l of precipitant solution (7% PEG4000, 0.1 M Tris-HCl (pH 8.5), 100 mM MgCl 2 , 166 mM imidazole (pH 7.0)). The reproducibility and quality of crystals were further improved by the micro-seeding method. The crystals were soaked in cryoprotectant made of mother liquor supplemented with 30% PEG400, before being flash frozen in liquid nitrogen. For the complex of DNMT3A (either wild-type or R836A mutant) with DNMT3L and the 25-mer DNA, crystals were generated by the hanging-drop vapour-diffusion method at 4 °C, from drops mixed from 1.5 μ l of the protein solution and 1.5 μ l of precipitation solution (0.1 M Tris-HCl (pH 7.0), 200 mM NaH 2 PO 4 , and 5% PEG4000). The crystals were treated with cryoprotectant containing the precipitation solution and 30% glycerol before collecting.
X-ray diffraction datasets for the covalent DNMT3A-DNMT3L-DNA complexes were collected at selenium peak wavelength on the BL501 or BL502 beamlines at the Advanced Light Source, Lawrence Berkeley National Laboratory, and the dataset for the covalent DNMT3A (R836A)-DNMT3L-DNA complex was collected on the 24-ID-E NE-CAT beamline at the Advanced Photon Source, Argonne National Laboratory. The diffraction data were indexed, integrated, and scaled using the HKL 2000 program 29 or the XDS program 30 . The structures of the productive covalent complexes of DNMT3A-DNMT3L-DNA were solved using the molecular replacement method in PHASER 31 , with the DNA-free structure of DNMT3A-DNMT3L (PDB 2QRV) serving as a search model. Further modelling of the covalent DNMT3A-DNMT3L-DNA complexes was performed using COOT 32 and then subject to refinement using the PHENIX software package 33 . The same R-free test set was used throughout the refinement. The final models for DNMT3A-DNMT3L complexed with the 25-mer and 10/11-mer DNAs were refined to 2.65 Å and 3.1 Å resolution, respectively. The final model for DNMT3A (R836A)-DNMT3L complexed with the 25-mer DNA was refined to 3.0 Å resolution.
The statistics for data collection and structural refinement of the productive covalent DNMT3A-DNMT3L-DNA complexes are summarized in Extended Data Fig. 1c . In vitro DNA methylation assay. Synthesized (GAC) 12 , (AAC) 12 and (TAC) 12 DNA duplexes were used as CG-, CA-and CT-containing substrates, respectively. The DNA methylation assays were performed in triplicate at 37 °C for 1 h, unless otherwise indicated. In brief, a 20-μ l reaction mixture contained 2.5 μ M S-adenosyl-l-[methyl-3 H]methionine (AdoMet) (specific activity 18 Ci mmol −1 , PerkinElmer), 0.3 μ M DNMT3A-DNMT3L, 0.75 μ M DNA in 59 mM Tris-HCl, pH 8.0, 0.05% β -mercaptoethanol, 5% glycerol, and 200 μ g ml −1 BSA. The methylation reactions were stopped by flash freezing in liquid nitrogen, followed by precipitation and incubation on ice for 1 h, in 1 ml of 15% trichloroacetic acid solution plus 40 μ g ml −1 BSA. The trichloroacetic acid-precipitated samples were then passed through a GF/C filter (GE Healthcare) using a vacuum-filtration apparatus. After sequential washing with 2 × 5 ml of cold 10% trichloroacetic acid and 5 ml of ethanol, the filters were dried and transferred to scintillation vials filled with 5 ml of ScintiVerse (Fisher), followed by measurement of tritium scintillation with a Beckman LS6500 counter. Plasmid construction. Full-length human DNMT3A isoform 1 was cloned into the EcoRI site of the pPyCAGIZ vector (a gift from J. Wang). DNMT3A mutation was generated by a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent). To achieve co-expression of the wild-type and mutant DNMT3A at equal levels in cells, we engineered a T2A-based fusion construct consisting of the mutant cDNA, which was added with an N-terminal 3× Flag-(GGGGS) 3 -Myc tag to differentiate its protein size from non-tagged wild-type DNMT3A, followed by a T2A peptide sequence at its C terminus and the cDNA of non-tagged wild-type DNMT3A. Myc-tagged full-length human DNMT3A isoform 1 was cloned into MSCV Pac retroviral vector as previously described 24 . All plasmid sequences were verified by sequencing. Cell lines and cell culture. Dnmt3a, Dnmt3b, and Dnmt1 TKO mouse ES cells (a gift from M. Okano) 16 were cultivated on gelatin-coated dishes in the highglucose DMEM base medium (Invitrogen) supplemented with 15% of fetal bovine serum (FBS, Invitrogen), 1× non-essential amino acids (Invitrogen), 0.1 mM β -mercaptoethanol, and 1,000 U ml −1 leukaemia inhibitory factor (ESGRO). The TF-1 human erythroleukaemic cell line was obtained from American Type Culture Collection (ATCC) and cultivated in the RPMI 1640 base medium (Invitrogen) supplemented with 10% of FBS and 2 ng ml −1 of recombinant human granulocytemacrophage colony-stimulating factor (GM-CSF; R&D Systems). Acquisition of the cytokine-independent growth of TF-1 cells by the introduction of cancerassociated gene mutation was examined and quantified upon GM-CSF removal as previously described 26 .
Authentication of cell line identities, including those of parental and derived lines, was ensured by the Tissue Culture Facility affiliated to the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center using the genetic signature profiling and fingerprinting analysis previously described 34 . Every 1-2 months, a routine examination of cell lines in culture for any possible mycoplasma contamination was performed using commercially available detection kits (Lonza Walkersville). Generation of stable cell lines. TKO ES cells were transfected by Lipofectamine 2000 (Invitrogen) with the pPyCAGIZ empty vector or that carrying wild-type or mutant DNMT3A. Forty-eight hours after transfection, the transduced ES cells were selected out in 50 μ g ml −1 Zeocin (Invitrogen) for 10 days. The pooled stable-expression cell lines and independent single-cell-derived clonal lines were continuously maintained in the medium with 25 μ g ml −1 zeocin. To generate TF-1 leukaemia cell lines with stable expression of wild-type or mutant DNMT3A, the MSCV-based retrovirus was packaged in HEK293 cells and used for infection as previously described 35 . Forty-eight hours after infection, TF-1 cells were selected by 2 μ g ml −1 puromycin for 4 days and maintained in medium with 1 μ g ml −1 puromycin. Western blotting. Antibodies used for western blotting were anti-MYC (Sigma-Aldrich, 9E10), anti-DNMT3A (Santa Cruz, H-295), anti-β -actin (Santa Cruz, sc-47778), and α -tubulin (Sigma-Aldrich). Total protein samples were prepared by cell lysis with SDS-containing Laemmli sample buffer followed by brief sonication. Extracted samples equivalent to 100,000 cells were loaded to the SDS-PAGE gels for western blot analysis. Quantification of 5-methyl-2′-deoxycytidine and 2′-deoxyguanosine in genomic DNA. The measurement procedures for 5-methyl-2′ -deoxycytidine (5-mdC) and 2′ -deoxyguanosine in genomic DNA were described previously 36, 37 . In brief, 1 μ g of genomic DNA prepared from cells was enzymatically digested into nucleoside mixtures. Enzymes in the digestion mixture were removed by chloroform extraction, and the resulting aqueous layer was concentrated to 10 μ l and subjected directly to LC-MS/MS and LC-MS/MS/MS analysis for quantification of 5-mdC and 2′ -deoxyguanosine, respectively. The amounts of 5-mdC and 2′ -deoxyguanosine (in moles) in the nucleoside mixtures were calculated from area ratios of peaks found in selected-ion chromatograms for the analytes over their corresponding isotope-labelled standards, the amounts of the labelled standards added (in moles), and the calibration curves. The final levels of 5-mdC, in terms of percentages of 2′ -deoxyguanosine, were calculated by comparing the amounts of 5-mdC relative to those of 2′ -deoxyguanosine. eRRBS and data analysis. Genomic DNA of each sample was added with 0.5% of unmethylated lambda DNA (Promega) as a spike-in control and subjected to eRRBS using MethylMidi-seq (Zymo Research) as described before 24 The water molecules are shown as purple spheres. g, Structure-based sequence alignment of DNMT3 proteins from human (hDNMT3A and hDNMT3B), mouse (mDnmt3a and mDnmt3b), and zebrafish (zDnmt3a and zDnmt3b). Completely conserved residues are coloured in white and highlighted in red. Partly conserved residues are coloured in red. Secondary structures are shown above the aligned sequences. The DNAbinding residues as revealed by this study are marked with black triangles.
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Extended Data Figure 4 | The essential roles for the CpG-engaging residues of DNMT3A, R836, and V716 in DNMT3A-mediated CpG versus non-CpG methylations. a, b, DNA methylation kinetics analysis of wild-type (DNMT3A WT , a) and R836A-mutated (DNMT3A R836A , b) DNMT3A using the CpG-, CpA-, or CpT-containing DNA substrates (n = 3 biological replicates). Purified DNMT3A-DNMT3L tetramer complex was used for measurements, followed by fitting with a first-order exponential equation. c, Ribbon representation of the crystal structure of DNMT3A R836A -DNMT3L tetramer in complex with the 25-mer DNA, with the CpG recognition by one of the DNMT3A monomers shown in expanded view. The 2F o − F c omit map of DNA was contoured at the 0.8σ level, and coloured in light blue. d, Methylation assay using either DNMT3A WT or DNMT3A V716G on CG-, CA-, and CT-containing DNA (n = 3 biological replicates). e, Immunoblots detect reconstituted expression of the indicated DNMT3A among TKO mouse ES cells, either the pooled stable-expression cell population or single-cell-derived clonal lines. EV, empty vector. A representative blot of two independent experiments is shown. For gel Source Data, see Supplementary Fig. 1 . f, LC-MS analysis reveals the global 5-methyl-2′deoxycytidine (5-mdC) levels (calculated as 5-mdC/2′ -deoxyguanosine on the y axis) in the TKO ES cells after stable transduction of empty vector or the indicated DNMT3A (n = 3 biological replicates). Data are mean ± s.d.
Extended Data Figure 8 | Effect of haematological cancer-associated mutations of DNMT3A on DNA methylation in vitro and in mouse TKO ES cells. a, Methylation kinetics of DNMT3A with mutations located at the catalytic loop, compared with DNMT3A WT . b, Methylation kinetics of DNMT3A with an active site mutation, R792H. c, Methylation kinetics of DNMT3A with mutations located at the TRD loop. d, Methylation kinetics of DNMT3A with the hotspot mutation R882H. For a-d, DNMT3A-DNMT3L complex was used for the measurements (n = 3 biological replicates), followed by fitting with a first-order exponential equation. These data were measured independently from those shown in Fig. 4c . e, Immunoblot detects stable reconstitution of DNMT3A WT or the indicated DNMT3A mutant in the TKO ES cells. A representative blot of two independent experiments is shown. For gel Source Data, see Supplementary Fig. 1 . f, LC-MS analysis reveals the global 5-methyl-2′ -deoxycytidine (5-mdC) levels (calculated as 5-mdC/ 2′ -deoxyguanosine) in the TKO ES cells after stable transduction of empty vector or the indicated DNMT3A. The methylation levels relative to TKO cells expressing DNMT3A WT are plotted. Data are mean ± s.d.; n = 4 biological replicates. g, Individual bisulfate sequencing detects the methylation level of cytosines in each sequence context within a major satellite DNA site at chromosome 2 in the TKO cells reconstituted with DNMT3A R836W (right), compared with DNMT3A WT (left) or DNMT3A R836A (middle; as determined in Fig. 3g) 
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Experimental design 1. Sample size
Describe how sample size was determined.
For various in vitro DNA methylation assays (Fig. 3c, 4c , Extended Data Fig. 4a,b,d , and Extended Data Fig. 8a-d,h) , three biological replicates were used and stated in figure legends. For cellular and genomics assays ( Fig. 3d-g, Fig. 4d -f, Extended Data Fig. 4e ,f, Extended Data Fig. 5-7 , Extended Data Fig. 8e -g, and Extended Data Fig. 9-10 ), at least three biological replicates were used and stated in figure legends.
Data exclusions
Describe any data exclusions.
One data point from Extended Data Fig.4a , three data points from Extended Data Fig. 8a-d and one data point from Extended Data Fig. 8h were identified as outliers and were excluded from analysis.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Data are presented as the mean ± SD of at least three independent experiments. Statistical analysis was performed with Student's t test for comparing two sets of data with assumed normal distribution. A p value of less than 0.05 was considered to be significant.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. N/A
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis. N/A Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons Test values indicating whether an effect is present Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
For structural study, the HKL2000, XDS, PHENIX, Coot and Pymol softwares were used for data processing and analysis. For eRRBS analysis, 'Bismark' software package was used. For DNA methylation array analysis, the R 'minfi' software package was used. Custom scripts used for eRRBS and 450K array analyses are available upon request.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
No restrictions
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Antibodies used for western blotting were α-MYC (Sigma, 9E10), α-DNMT3A ( Santa Cruz, H-295), anti-beta-Actin (Santa Cruz, sc-47778) and α-tubulin (Sigma). They were validated by the manufacturers. c. Report whether the cell lines were tested for mycoplasma contamination. 
